Table 4 of Dejneka, Mol Vis 2008; 14:997-1005.
Total bevasiranib present in tissue sample (ngs) 24 h following intravitreal injection | |||||||||
Animal ID | Treatment | Aqueous fluid | Vitreous fluid | Lens | Iris | Ciliary Body | RPE | Choroid | Retina |
A1/OS | D5W | <LLOQ | <LLOQ | <LLOQ | <LLOQ | NA | <LLOQ | <LLOQ | <LLOQ |
A1/OD | D5W | <LLOQ | <LLOQ | <LLOQ | <LLOQ | <LLOQ | <LLOQ | <LLOQ | <LLOQ |
B1/OS | D5W | <LLOQ | <LLOQ | <LLOQ | <LLOQ | NA | <LLOQ | <LLOQ | <LLOQ |
B1/OD | D5W | <LLOQ | <LLOQ | <LLOQ | <LLOQ | NA | <LLOQ | <LLOQ | <LLOQ |
A2/OS | Bevasiranib | 325.6 (0.02%) | >ULOQ | <LLOQ | 18,358.3 (0.92%) | 176.3 (0.01%) | 806.8 (0.04%) | 214.2 (0.01%) | 236.5 (0.01%) |
A2/OD | Bevasiranib | 2,170.5 (0.11%) | >ULOQ | <LLOQ | 1,572.3 (0.08%) | 12.7 (0.001%) | 422.6 (0.02%) | 58.2 (0.003%) | 2,335.1 (0.12%) |
B2/OS | Bevasiranib | 3,547.0 (0.18%) | >ULOQ | <LLOQ | 18,943.8 (0.95%) | 86.2 (0.004%) | 645.3 (0.03%) | 382.1 (0.02%) | 410.8 (0.02%) |
B2/OD | Bevasiranib | 4,043.0 (0.20%) | >ULOQ | 16,160.6 (0.81%) | 27,534.9 (1.38%) | 553.8 (0.03%) | >ULOQ | 1,298.5 (0.06%) | 749.8 (0.04%) |
E5/OD | Bevasiranib | 1,688.9 (0.08%) | 114,171.9 (5.71%) | <LLOQ | 2,371.0 (0.12%) | 6,396.6 (0.32%) | 2,695.6 (0.13%) | 2,139.9 (0.11%) | 1,690.2 (0.08%) |